NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. in the Southern District of New York, concerning alleged misleading statements in the company's Offering Documents related to its initial public offering on September 15, 2023 [1]. Group 1: Allegations Against Neumora - The lawsuit claims that Neumora made materially false and/or misleading statements in its Offering Documents [2]. - It is alleged that Neumora amended the Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2]. - The complaint also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].